ArticleFrontiers in oncology2025
Retrospective study of chidamide-containing regimens as maintenance therapy among T- and NK-cell lymphoma patients.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Pooled it
- Precision scalpels for the epigenome: next-gen editing tools in targeted therapies.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to explore the efficacy of chidamide-containing regimens as maintenance therapy in patients with T- and natural killer (NK)-cell lymphomas (TNKLs). Methods: A total of 51 patients with TNKLs who received chidamide-containing regimens after induction therapy were enrolled. The primary end point was progression-free survival (PFS), while the secondary end point was overall survival (OS) and safety. Results: The median duration of maintenance was 14 months (range = 1-24 months). Most of the patients were diagnosed with extranodal NK/T-cell lymphoma (ENKTCL; 24/51, 47.1%), followed by angioimmunoblastic T-cell lymphoma (AITL; 14/51, 27.5%). The median PFS and OS were 21 and 29 months, respectively. The 2-year PFS and OS among the overall population were 45.1% and 54.2%, respectively. Patients who experienced complete remission (CR) after induction therapy had favorable survival compared with non-CR patients (partial remission/stable disease, PR/SD). Patients who experienced CR after first-line induction treatment also had favorable survival, but similar significance was not observed in the salvage treatment group. Although 86.3% of the patients had chidamide-related adverse events (AEs), severe hematological AEs (grade ≥3) occurred in only 11 (21.6%) patients, indicating the safe toxicity profile of chidamide. Conclusion: The prolonged survival indicated that chidamide-containing maintenance therapy is promising and well tolerated in patients with TNKLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.